Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Investors will be able to hear Intelligent Bio Solutions discuss its FDA 510(k) submission, clinical data and ex-U.S. commercial progress in a live webcast.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intelligent Bio Solutions (INBS) will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET.
The moderated discussion will feature President and CEO Harry Simeonidis and Vice President of Product Development Peter Passaris. Topics include the company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, supporting clinical data, the FDA review process, and commercial progress outside the United States. The event will be accessible via live webcast through an online registration link, with a replay available on the company’s investor relations website after the session.
Details
News Market Reaction – INBS
On Sep 10, the day this news came out, INBS closed 2.23% below the previous close. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 10 session.
Key Terms
510(k) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET.
The moderated discussion will feature Harry Simeonidis, President and CEO, and Peter Passaris, Vice President of Product Development. Topics will include the Company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, the supporting clinical data, the FDA review process, and the Company’s commercial progress outside the United States.
Event Details
- Date: Thursday, September 24, 2026
- Time: 4:30 p.m. ET
- Format: Virtual fireside chat, followed by a live Q&A session
- Webcast Registration: https://us02web.zoom.us/webinar/register/WN_vWXs5KeQSYCxSxhmR5_bVQ
A live webcast of the event will be available through the registration link above. A replay of the presentation will be made available on the Company’s investor relations website following the event.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
